Sorafenib
Sorafenib
复制标题
DOI：
10.1007/978-3-642-01222-8_5
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Hasskarl, Jens
中科院分区：
文献类型：
--
作者：
Hasskarl, Jens
索拉非尼（BAY 43-9006，Nexavar (R)）是一种新型口服激酶抑制剂，在体内和体外针对多种酪氨酸激酶。主要靶标是癌症中经常失调的受体酪氨酸激酶通路，例如 rafras 通路、血管内皮生长因子 (VEGF) 通路和 FMS 样酪氨酸激酶 3 (FLT3)。索拉非尼已获得 FDA 快速通道批准，用于治疗晚期肾细胞癌和肝细胞癌，并在甲状腺癌中显示出良好的临床活性。正在进行多项临床试验以进一步研究索拉非尼单独或联合治疗各种肿瘤实体的作用。
Sorafenib (BAY 43-9006, Nexavar (R)) is a novel oral kinase inhibitor that targets multiple tyrosine kinases in vivo and in vitro. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the rafras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3). Sorafenib was approved by the FDA in fast track for advanced renal cell cancer and hepatocellular cancer and shows good clinical activity in thyroid cancer. Multiple clinical trials are undertaken to further investigate the role of sorafenib alone or in combination for the treatment of various tumor entities.